Effect of edaravone-urinary kallidinogenase combination treatment on acute cerebral infarction

Purpose: To investigate the curative effect of edaravone in combination with urinary kallidinogenase in the treatment of acute cerebral infarction and its effect on serum high-sensitivity C-reactive protein (hsCRP) and interleukin (IL). Methods: One hundred and eighty patients with acute cerebral infarction (ACI) who were on admission from March 2015 to July 2016 participated in this study as research subjects. They were assigned to study group (59 patients) and control group (59 patients). Edaravone and conventional treatment were administered to the control group. In contrast, in addition to conventional treatment, the study group was given edaravone in combination with urinary kallidinogenase. Clinical effects, neurological function and serum IL-17 and hs-CRP levels in the two groups were determined. Results: The overall response of the study group was significantly higher than that of the control group (p < 0.05). Scores in the National Institute of Health stroke scale (NIHSS) were reduced in both groups, and modified Barthel index (MBI) of both groups remarkably increased, when compared to values before treatment. Improvements in NIHSS score and MBI of the study group were higher than those of the control group (p < 0.05). Serum IL-17 and hs-CRP levels declined significantly in the two groups (p < 0.05), but post-treatment serum IL-17 and hs-CRP levels of the study group were significantly reduced, relative to control values (p < 0.05). There were no significant differences in incidence of adverse reactions between the two groups. Conclusion: The use of edaravone in combination with urinary kallidinogenase in the treatment of ACI can significantly reduce serum IL-17 and hs-CRP levels without inducing severe adverse reactions.